ReViral: Pfizer's $525 Million Acquisition of ReViral
Goodwin advised ReViral on the deal. ReViral announced its acquisition by Pfizer. Pfizer will acquire ReViral for a total consideration of up to $525 million, including up [...]
Read full article »
Reviral is an England-based biopharmaceutical company that develops and commercializes antiviral therapeutics for the treatment of the respiratory syncytial virus.
Read more